NASDAQ:MLTX MoonLake Immunotherapeutics (MLTX) Stock Price, News & Analysis → After Conviction, More Bad News for Trump (From Paradigm Press) (Ad) Free MLTX Stock Alerts $41.67 -0.77 (-1.81%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$41.62▼$42.8050-Day Range$38.66▼$48.6052-Week Range$24.31▼$64.98Volume181,154 shsAverage Volume332,893 shsMarket Capitalization$2.66 billionP/E RatioN/ADividend YieldN/APrice Target$74.46 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get MoonLake Immunotherapeutics alerts: Email Address MoonLake Immunotherapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside78.7% Upside$74.46 Price TargetShort InterestBearish14.02% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.11Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.16) to ($1.66) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.90 out of 5 starsMedical Sector749th out of 905 stocksPharmaceutical Preparations Industry357th out of 430 stocks 3.4 Analyst's Opinion Consensus RatingMoonLake Immunotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 9 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageMoonLake Immunotherapeutics has only been the subject of 4 research reports in the past 90 days.Read more about MoonLake Immunotherapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted14.02% of the float of MoonLake Immunotherapeutics has been sold short.Short Interest Ratio / Days to CoverMoonLake Immunotherapeutics has a short interest ratio ("days to cover") of 16.3, which indicates bearish sentiment.Change versus previous monthShort interest in MoonLake Immunotherapeutics has recently increased by 5.05%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMoonLake Immunotherapeutics does not currently pay a dividend.Dividend GrowthMoonLake Immunotherapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MLTX. Previous Next 2.3 News and Social Media Coverage News SentimentMoonLake Immunotherapeutics has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for MoonLake Immunotherapeutics this week, compared to 3 articles on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MoonLake Immunotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.02% of the stock of MoonLake Immunotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions93.85% of the stock of MoonLake Immunotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about MoonLake Immunotherapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for MoonLake Immunotherapeutics are expected to decrease in the coming year, from ($1.16) to ($1.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MoonLake Immunotherapeutics is -55.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MoonLake Immunotherapeutics is -55.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMoonLake Immunotherapeutics has a P/B Ratio of 5.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about MoonLake Immunotherapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Daily Market AlertsTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world's most powerful tech companies (including Microsoft, Intel, and Google) investing billions. And one tiny company will be the driving force behind this new tech revolution…Click below for your free report "Top 5 Tech Stocks to Buy in 2024", About MoonLake Immunotherapeutics Stock (NASDAQ:MLTX)MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.Read More MLTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MLTX Stock News HeadlinesJune 4, 2024 | americanbankingnews.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Receives $74.46 Average PT from AnalystsMay 17, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for MoonLake Immunotherapeutics Amidst Promising Clinical Trials and Strategic Development PlansMay 16, 2024 | globenewswire.comMoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativaMay 12, 2024 | seekingalpha.comMoonLake Immunotherapeutics' Competitive Edge In Autoimmune Market ExpansionMay 10, 2024 | markets.businessinsider.comMoonLake Immunotherapeutics Buy Rating Justified by Strong Clinical Execution and Financial PositionMay 8, 2024 | markets.businessinsider.comMoonLake Immunotherapeutics Earns Buy Rating: Advancing Clinical Programs and Strong Financial PositionMay 8, 2024 | markets.businessinsider.comMoonLake Immunotherapeutics’ Strong Buy Rating: Promising Clinical Developments and Significant Market PotentialMay 8, 2024 | finance.yahoo.comMoonLake Immunotherapeutics Reports Q1 2024 Financial OutcomesMay 7, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX) and Curis (CRIS)May 7, 2024 | finance.yahoo.comMoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business UpdateApril 26, 2024 | markets.businessinsider.comStrong Buy Rating for MoonLake Immunotherapeutics Based on Promising Sonelokimab Clinical Trials and Market PotentialApril 23, 2024 | markets.businessinsider.comMoonLake Immunotherapeutics: A Promising Outlook with Sonelokimab’s Potential in the HS MarketApril 23, 2024 | markets.businessinsider.comBuy Rating Affirmed for MoonLake Immunotherapeutics Amid Promising Clinical Results for SonelokimabApril 11, 2024 | markets.businessinsider.comMoonLake Immunotherapeutics Buy Rating: Strategic Partnerships and Market Potential Fuel OptimismApril 10, 2024 | globenewswire.comMoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditionsApril 10, 2024 | businesswire.comMoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint ConditionsApril 2, 2024 | msn.comGoldman starts MoonLake at neutral, cites lead drug potentialMarch 25, 2024 | finance.yahoo.comMLTX Aug 2024 80.000 callMarch 12, 2024 | finance.yahoo.comMLTX May 2024 60.000 callMarch 12, 2024 | finance.yahoo.comMLTX Apr 2024 40.000 putMarch 11, 2024 | marketwatch.comMoonLake Immunotherapeutics Shares Rise Premarket After Pipeline UpdateMarch 11, 2024 | msn.comWhy Is Inflammatory Disease-Focused MoonLake Immunotherapeutics Stock Trading Higher Today?March 11, 2024 | realmoney.thestreet.comMoonLake price target raised to $100 from $75 at H.C. WainwrightMarch 10, 2024 | globenewswire.comMoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D DayMarch 4, 2024 | markets.businessinsider.comBuy Rating Affirmed for MoonLake Immunotherapeutics Amid Promising Clinical and Regulatory AdvancesSee More Headlines Receive MLTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MoonLake Immunotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/12/2024Today6/07/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MLTX CUSIPN/A CIK1821586 Webwww.moonlaketx.com Phone41-41-510-8022FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Stock Price Target$74.46 High Stock Price Target$100.00 Low Stock Price Target$56.00 Potential Upside/Downside+78.7%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($0.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,010,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-7.92% Return on Assets-7.76% Debt Debt-to-Equity RatioN/A Current Ratio62.12 Quick Ratio62.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.15 per share Price / Book5.11Miscellaneous Outstanding Shares63,890,000Free Float56,208,000Market Cap$2.66 billion OptionableOptionable Beta1.25 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Jorge Santos da Silva (Age 46)Co-Founder, CEO & Director Comp: $1.11MDr. Kristian Reich (Age 58)Co-Founder & Chief Scientific Officer Comp: $1.2MMr. Matthias Bodenstedt (Age 36)Chief Financial Officer Comp: $588.25kMr. Oliver DaltropChief Technical OfficerNicolas MosimannGeneral CounselLuciana MarquesDirector of HR, People & CultureMs. Nuala BrennanChief Clinical Development OfficerMore ExecutivesKey CompetitorsDocGoNASDAQ:DCGOQuantum-SiNASDAQ:QSIAppHarvestNASDAQ:APPHCatalentNYSE:CTLTElanco Animal HealthNYSE:ELANView All CompetitorsInsiders & InstitutionsIkarian Capital LLCSold 42,600 shares on 5/17/2024Ownership: 0.000%Kennedy Capital Management LLCSold 8,622 shares on 5/16/2024Ownership: 0.042%California State Teachers Retirement SystemBought 429 shares on 5/16/2024Ownership: 0.026%Affinity Asset Advisors LLCBought 4,012 shares on 5/15/2024Ownership: 0.117%Bellevue Group AGBought 4,400 shares on 5/15/2024Ownership: 0.007%View All Insider TransactionsView All Institutional Transactions MLTX Stock Analysis - Frequently Asked Questions Should I buy or sell MoonLake Immunotherapeutics stock right now? 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MoonLake Immunotherapeutics in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MLTX shares. View MLTX analyst ratings or view top-rated stocks. What is MoonLake Immunotherapeutics' stock price target for 2024? 12 analysts have issued 12 month price objectives for MoonLake Immunotherapeutics' shares. Their MLTX share price targets range from $56.00 to $100.00. On average, they expect the company's share price to reach $74.46 in the next year. This suggests a possible upside of 78.7% from the stock's current price. View analysts price targets for MLTX or view top-rated stocks among Wall Street analysts. How have MLTX shares performed in 2024? MoonLake Immunotherapeutics' stock was trading at $60.39 on January 1st, 2024. Since then, MLTX shares have decreased by 31.0% and is now trading at $41.67. View the best growth stocks for 2024 here. When is MoonLake Immunotherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our MLTX earnings forecast. How were MoonLake Immunotherapeutics' earnings last quarter? MoonLake Immunotherapeutics (NASDAQ:MLTX) released its quarterly earnings results on Sunday, May, 12th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.03. What ETFs hold MoonLake Immunotherapeutics' stock? ETFs with the largest weight of MoonLake Immunotherapeutics (NASDAQ:MLTX) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC), Harbor Health Care ETF (MEDI) and Goldman Sachs Future Health Care Equity ETF (GDOC).First Trust Nasdaq Pharmaceuticals ETF (FTXH). Who are MoonLake Immunotherapeutics' major shareholders? MoonLake Immunotherapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (3.34%), Westfield Capital Management Co. LP (1.43%), Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. (0.36%), TimesSquare Capital Management LLC (0.33%), Decheng Capital LLC (0.26%) and Ikarian Capital LLC (0.00%). Insiders that own company stock include Bihua Chen, Da Silva Jorge Santos, Kristian Reich and Matthias Bodenstedt. View institutional ownership trends. How do I buy shares of MoonLake Immunotherapeutics? Shares of MLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MLTX) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | SponsoredNvidia has Apple and Microsoft within striking rangeA small handful of companies are working with Nvidia to help ensure that this pivot is a massive success. W...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MoonLake Immunotherapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share MoonLake Immunotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.